KFDA to strengthen monitoring of Lamisil cream

The Korea Food and Drug Administration (KFDA) recently said it will strengthen monitoring of Lamisil cream marketed by Norvartis Korea in response to the occurrence of its side effect vitiligo, which was reported by a pharmacist living in Pyungtaik, Kyunggi Province.

Vitiligo is a pigmentation disorder in which melanocytes in the skin, the mucous membranes, and the retina are destroyed.

T...